{"id":"NCT00577824","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)","officialTitle":"Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2007-12-20","resultsPosted":"2009-12-31","lastUpdate":"2015-04-09"},"enrollment":181,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["LY2148568","Byetta"]},{"type":"DRUG","name":"exenatide","otherNames":["LY2148568","Byetta"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.","primaryOutcome":{"measure":"Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24","timeFrame":"baseline, 24 weeks","effectByArm":[{"arm":"5mcg Exenatide BID","deltaMin":-1.34,"sd":0.11},{"arm":"10mcg Exenatide BID","deltaMin":-1.62,"sd":0.11},{"arm":"Placebo BID","deltaMin":-0.28,"sd":0.15}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":12,"countries":["Japan"]},"refs":{"pmids":["24843486","24843529","22913891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":72},"commonTop":["Hypoglycemia","Nausea","Blood glucose decreased","Nasopharyngitis","Constipation"]}}